Notable Newcomers: These 2025 IPOs Dominated the Year

In 2025 fewer than a quarter of the more than 200 U.S. IPOs outpaced the S&P 500’s 18% total return, but three standouts—Karman (KRMN), Circle Internet Group (CRCL) and Hinge Health (HNGE)—handily beat the market. KRMN (IPO $22 on Feb. 13) finished just above $73 (+~230%), with accelerating revenue growth (21% in Q1 to 42% in the last quarter) and a 41% gross margin; consensus target $80.43 implies ~5% upside. CRCL (IPO $31 on June 5) closed the year just above $79 (+~150%, with a 168% first-day surge), reported revenue up 66% and USDC circulation +108% to $73.7bn; consensus target $141.18 (post-Nov. 12 update avg ~$101) implies 21–69% upside depending on the set. HNGE (IPO $32 on May 22) ended near $46.50 (+~45%), with revenue +53%, free cash flow margin rising to ~53% from 27% YoY (FCF up ~200% last quarter) and 2,560 organizational clients; consensus target just under $60 (post-Nov. 4 updated avg $67) implies ~32–47% upside.

Analysis

Market structure: 2025’s winners (KRMN, CRCL, HNGE) signal bifurcated demand: mission‑critical defense components and digital healthcare services are tightening supply vs. demand (KRMN rev +42% q/q acceleration; HNGE rev +53% y/y), while stablecoins (CRCL USDC +108% y/y) are capturing payment flow from legacy rails. Direct beneficiaries are prime defense contractors, digital health payers and blockchain payment rails; losers include low‑margin physical therapy franchises and incumbent payment processors. Cross‑asset: a durable defense/tech re‑rating would compress credit spreads for rated A‑name defense suppliers, lift industrial commodity inputs for specialty alloys, and raise small‑cap implied vols (CRCL shows very wide analyst target dispersion).

Risk assessment: key tail risks are regulatory (SEC/Treasury stablecoin rule in next 60–180 days), large contract reversals (DoD order freeze or prime consolidation), and clinical/regulatory setbacks for HNGE’s device. Time horizons: immediate (days) = IPO momentum/first‑day price action; short term (weeks–months) = post‑earnings guidance and regulatory comments; long term (quarters–years) = contract conversion, payer adoption, and reserve/accounting changes. Hidden dependencies: CRCL depends on banking/custody partnerships and full‑reserve optics; KRMN depends on a handful of primes for >50% of backlog; HNGE depends on sustained payer reimbursement and client retention rates. Catalysts: next 2–4 earnings, SEC stablecoin rulemaking, FY2026 DoD budgeting cycles.

Trade implications: tactical: overweight HNGE (healthcare tech) and underweight/trim KRMN after >230% run; implement defined‑risk option structures for CRCL to play regulatory binary. Specifics: small core long in HNGE sized 2–3% of portfolio with 6–12 month horizon; trim KRMN holdings by ~40% and sell 30–60 day covered calls around analyst target ($80) to harvest premium; for CRCL use 9–12 month call spreads to express bullishness only if USDC growth sustains >20% q/q or regulatory language is favorable. Sector rotation: add digital healthcare and selective A&D suppliers with multi‑year backlog visibility; reduce exposure to speculative IPO momentum names.

Contrarian angles: consensus underestimates regulatory drag on CRCL (targets $60–$190 reflect noise); KRMN’s tiny implied upside (~5% to $80) makes it vulnerable to mean reversion if growth decelerates below ~25% y/y. Conversely, HNGE’s margin expansion (FCF margin 53%) and 2,560 enterprise clients look underpriced versus a $60–$67 analyst range—this is a candidate for durable secular growth. Historical parallels: fintech/crypto IPO froth (2019–21) shows fast repricing when reserve/accounting transparency is required; unintended consequence: rapid USDC growth materially increases scrutiny that could impose capital/custody costs on Circle, compressing take‑rates.

Key Decisions for Investors

• Establish a 2–3% long position in HNGE (buy shares or buy 9–12 month $40–$60 call spread) with a 6–12 month horizon; add another 1–2% if next two quarters show revenue growth >35% and FCF margin >40%. Set stop‑loss at 20% below entry or on client count decline >5% q/q.
• Trim existing KRMN exposure by ~40% to lock gains; sell 30–60 day covered calls at the $80 strike to collect premium (roll if implied vol falls). Re‑enter only on confirmed pullback below $60 or after a beat‑and‑raise that reestablishes >30% y/y revenue growth.
• Avoid large directional exposure to CRCL until regulatory clarity; instead allocate 0.5–1% to a defined‑risk bullish 12‑month call spread (e.g., buy Jan 2027 $75 call, sell Jan 2027 $150 call) sized to portfolio risk. Increase only if USDC circulation growth sustains >20% q/q for two consecutive quarters or SEC guidance explicitly preserves redeemability/reserve treatment.
• Monitor three near‑term catalysts and act: (1) SEC/Treasury stablecoin rule updates in next 30–90 days — if rules demand 100% bank‑like reserves, reduce CRCL to zero; (2) FY2026 DoD procurement notices over next 90–180 days — add to KRMN only on multi‑year award visibility; (3) next two HNGE earnings — if retention falls >10% or FCF margin drops below 30%, cut position by half.